Batavia Biosciences is a contract development and manufacturing organization with expertise in viral vaccines, virotherapy, proteins and antibodies. We are not your standard CDMO – our customers regularly refer to us as their product development partner and thought partner.
How Batavia helps to reduce human suffering from infectious diseases and cancer
We accelerate the journey to the clinic by improving product yields, reducing process development time and increasing product stability. Our services and technologies have demonstrated to reduce risks, improve timelines and reduce costs in biopharmaceutical development to ensure the product reaches the patient without any unnecessary delays.
100
experts with industry experience
500
projects successfully completed
97
successful runs under GMP
70
returning customers
Latest resources from learning center
Leiden, The Netherlands, June 28, 2022 – Today, Batavia Biosciences announces that it will extend its CDMO services portfolio (R&D and clinical manufacturing) to include commercial manufacturing services. The company…
It is with great enthusiasm and excitement that we would like to congratulate Leiden University Medical Center and the research team on their recent accomplishment using the lentivirus. Researchers have successfully…
Leiden, The Netherlands, June 14, 2022 – Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities in the Netherlands. The infrastructure increases capacity with another 22,500 sq.…
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective
Adenoviruses are being explored as vectors for cardiovascular gene therapy purposes against many heritable diseases. Gene transfer vectors, based on human adenovirus serotype 5, were some of the first developed…
Talk to our experts
